FFNP-PET could aid breast cancer treatment evaluation

PET imaging with fluoro furanyl norprogesterone (FFNP) could provide a new...Read more on AuntMinnie.comRelated Reading: JNM: Imaging agents predict endocrine therapy response
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

We reported nodal and breast downstaging rates with NET, and compared axillary response rates following NET and neoadjuvant chemotherapy (NAC).MethodsConsecutive stage I –III breast cancer patients treated with NET and surgery from January 2009 to December 2019 were identified from a prospectively maintained database. Nodal pCR rates were compared between biopsy-proven node-positive patients treated with NET, and HR+/HER2- patients treated with NAC from November 2 013 to July 2019.Results127 cancers treated with NET and 338 with NAC were included. NET recipients were older, more likely to have lobular and lower-grade...
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
In this study, we found that ZBTB1 is down-regulated in breast cancer and this down-regulation is associated with poor outcome of breast cancer patients. ZBTB1 suppresses breast cancer cell proliferation and tumor growth. The majority of breast cancers are estrogen receptor (ER) positive and selective estrogen receptor modulators such as tamoxifen have been widely used in the treatment of these patients. Unfortunately, many patients develop resistance to endocrine therapy. Tamoxifen-resistant cancer cells often exhibit higher HER2 expression and an increase of glycolysis. Our data revealed that ZBTB1 plays a critical role ...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Molecular Bases of Disease Source Type: research
ConclusionWe identified that religion and/or spirituality helps women with their adjustment to breast cancer and influences their continued use and management of side-effects from AET.Implications for breast cancer survivorsThis study illustrates the importance of developing meaning-centered interventions that harness religion and spirituality to help women cope with AET. Our findings support the development of interventions that work to enhance AET persistence among breast cancer survivors.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
TUESDAY, Oct. 6, 2020 -- For patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), high-risk early breast cancer (EBC), the addition of abemaciclib to endocrine therapy (ET) increases the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
TUESDAY, Oct. 6, 2020 -- For patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 −), high-risk early breast cancer (EBC), the addition of abemaciclib to endocrine therapy (ET) increases the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
This study provided first ‐hand data regarding the efficacy and safety profile of fulvestrant 500 mg in Chinese patients with HR+/HER2‐ MBC. We successively collected all patients treated with fulvestrant within a certain period of time to delineate the pattern of real‐world practice. The study identified potential de terminants that were significantly associated with PFS of fulvestrant 500 mg. AbstractFulvestrant 500  mg is standard of care for endocrine therapy‐naive or pretreated women with hormone receptor‐positive (HR+) metastatic breast cancer (MBC). This study was conducted to explore the po...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
AbstractPurpose of ReviewWhile the majority of hormone receptor –positive breast cancers are diagnosed at an early stage, a significant proportion of patients will develop disease recurrence, especially late disease recurrence, despite current therapeutic approaches. In this review, we examine the data pertaining to the choice of endocrine and extended endocri ne therapy, outline how to identify patients that may benefit from extended therapy, and discuss prognostic tools to assist with patient selection.Recent FindingsThe risk of breast cancer recurrence persists after 5  years, is cumulative, and is indefinite...
Source: Current Oncology Reports - Category: Cancer & Oncology Source Type: research
Abstract Distant metastases from breast cancer are frequently found in bones, lungs and the liver. Metastasis to the stomach is rare, and its clinical presentation remains unclear. The present report describes a case of isolated gastric metastasis from breast cancer identified by contrast-enhanced computed tomography (CT). A 45-year-old female patient underwent right mastectomy and axillary lymph node dissection after preoperative chemotherapy for right invasive lobular breast carcinoma T4bN2M0, stage IIIB. Postoperative radiotherapy and endocrine therapy with tamoxifen for 5 years were performed. CT for postopera...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research
rauch H Abstract PURPOSE: Patients with estrogen and/or progesterone receptor-positive, early breast cancer benefit from hormonal treatment, yet high global death burdens due to high prevalence and long-term recurrence risk call for biomarkers to guide additional treatment approaches. EXPERIMENTAL DESIGN: From a prospective, observational study of postmenopausal early breast cancer patients treated with tamoxifen or aromatase inhibitors gene expression analyses of 612 tumors was performed using the NanoString® Breast Cancer 360 panel to interrogate 23 breast cancer pathways. Candidate signatures associate...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Hypoxia-inducible factors (HIFs) and the HIF-dependent cancer hallmarks angiogenesis and metabolic rewiring are well-established drivers of breast cancer aggressiveness, therapy resistance, and poor prognosis. Targeting of HIF and its downstream targets in angiogenesis and metabolism has been unsuccessful so far in the breast cancer clinical setting, with major unresolved challenges residing in target selection, development of robust biomarkers for response prediction, and understanding and harnessing of escape mechanisms. This Review discusses the pathophysiological role of HIFs, angiogenesis, and metabolism in breast can...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Radiology